Biohaven Ltd. (NYSE:BHVN) is one of the 10 Stocks Making Investors Richer.
Biohaven soared by 12.66 percent on Wednesday to close at $13.62 apiece, as investors positioned their portfolios ahead of the initiation of two pivotal studies for its endometrial and urothelial cancer treatment candidates by the end of the month.
Based on its key milestone calendar, Biohaven Ltd. (NYSE:BHVN) is set to initiate clinical studies for its BHV-1510 for advanced or metastatic epithelial tumors, as well as the BHV-1530 for urothelial cancer and other tumors, in the first half of the year.
Photo by George Morina on Pexels
Apart from the said pipelines, Biohaven Ltd. (NYSE:BHVN) is also planning to initiate pivotal studies for BHV-1400 for the treatment of IgAN, or Berger disease, as well as BHV-1300 for Graves ‘ disease, in the middle of the year.
Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology.
In the first quarter of the year, it was able to slash its net losses by 41 percent to $130.5 million from $221.7 million in the same period last year. It has yet to generate revenues as of the period.
While we acknowledge the potential of BHVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.